State of Alaska Department of Revenue Boosts Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

State of Alaska Department of Revenue boosted its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 16.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,938 shares of the medical instruments supplier’s stock after purchasing an additional 1,921 shares during the quarter. State of Alaska Department of Revenue owned about 0.06% of ICU Medical worth $2,539,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Motco purchased a new stake in shares of ICU Medical during the 1st quarter valued at about $29,000. Innealta Capital LLC bought a new stake in ICU Medical during the second quarter worth approximately $32,000. Hexagon Capital Partners LLC raised its position in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares during the period. Allworth Financial LP raised its position in ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares during the period. Finally, EntryPoint Capital LLC lifted its stake in shares of ICU Medical by 731.5% in the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares in the company, valued at approximately $645,901.02. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the transaction, the vice president now directly owns 4,482 shares of the company’s stock, valued at $645,901.02. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,552 shares of company stock worth $6,679,322 in the last ninety days. 6.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Jefferies Financial Group began coverage on ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. KeyCorp upped their price target on shares of ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Finally, Raymond James raised their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.25.

ICU Medical Trading Down 2.7 %

NASDAQ ICUI opened at $170.73 on Friday. The stock has a market cap of $4.17 billion, a PE ratio of -58.47 and a beta of 0.66. ICU Medical, Inc. has a 12 month low of $78.28 and a 12 month high of $188.53. The company’s 50-day moving average price is $173.70 and its 200-day moving average price is $136.46. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. The business had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.58 EPS. Equities research analysts forecast that ICU Medical, Inc. will post 3.81 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.